Summary: Prostaglandin (PG) E 2 is involved in neuroinflammation and neurotoxicity, and the cerebral PGE 2 concentration is increased in neurodegenerative diseases. Because the intracerebral concentration of L-glutamate (L-Glu) is reported to be also elevated in neurodegenerative diseases, it has been proposed that L-Glu affects PGE 2 dynamics in the brain, and thus exacerbates neural excitotoxicity. The purpose of this study was to investigate the effect of intracerebral L-Glu on PGE 2 elimination across the blood-brain barrier (BBB) in rats by using the intracerebral microinjection technique. [
Introduction
Prostaglandin E 2 (PGE 2 ), one of the eicosanoids, is involved in the modulation of synaptic signaling, excitability, and neuroinflammatory responses in the central nervous systems (CNS) under physiological and pathological conditions. 1, 2) Under normal conditions, the concentration of PGE 2 in the brain interstitial fluid (ISF) and cerebrospinal fluid (CSF) is maintained, at most, at 1 nM. 3) On the other hand, the level of PGE 2 in the brain is reported to be increased in various CNS diseases such as neural inflammation, seizure, and Alzheimer's disease and, thus, the neural excitatory signals and neurotoxicity are induced by the excess PGE 2 in the brain. 2, 4) Therefore, it is conceivable that PGE 2 in the brain is related to the pathogenesis and progression of neural excitation and toxicity in patients with CNS diseases. The cerebral accumulation of PGE 2 in the presence of CNS disease is caused by an imbalance in the rates of production and elimination of PGE 2 from the brain. PGE 2 is biosynthesized from arachidonate via cyclooxygenase and prostaglandin E synthetase (PGES), which are up-regulated under neuroinflammatory conditions. 5) Regarding the elimination of PGE 2 from the brain, the removal of PGE 2 from the brain ISF and CSF plays an important role in this process because the activity of 15-hydroxyprostaglandin dehydrogenase, an enzyme associated with PG catabolism, is reported to be almost undetectable in the brain. 6) The exchange of compounds between the circulating blood and brain/CSF is regulated by the blood-brain barrier (BBB) and blood-CSF barrier (BCSFB), 7, 8) and the BBB and BCSFB are formed of brain capillary endothelial cells (BCEC) and choroid plexus epithelial cells, respectively. These cells express various organic anion transporters which contribute to compound transport across the BBB and BCSFB, such as organic anion transporter 3 (Oat3/ Slc22a8), organic anion transporting polypeptide 1a4 (Oatp1a4/ Slco1a4), prostaglandin transporter (Pgt/Slco2a1), and multidrug resistance-associated protein 4 (Mrp4/Abcc4). [9] [10] [11] [12] [13] Of these transporters, it has been reported that Oat3, Pgt, and Mrp4 accept PGE 2 as a substrate. [14] [15] [16] Our previous studies have revealed that PGE 2 is eliminated from the brain across the BBB via Mrp4 in mice, 17, 18) while [ 3 H]PGE 2 in the circulating blood after intravenous administration is reported to be transported to the brain across the BBB in rats. 19) Regarding the carrier-mediated influx transport of PG at the BBB, Taogoshi et al. have reported that Oatp1a4 and/or Pgt are involved in PGE 1 influx transport at the BBB. 20) Taking these lines of evidence into consideration, it would seem that both brain-to-blood and blood-to-brain transport determine the net flux of PGE 2 transport at the BBB. As well as the BBB, the BCSFB contributes to the elimination of PGE 2 from the CSF via Pgt and Oat3 at the apical membrane of choroid plexus epithelial cells in rats.
14) Therefore, it is important to elucidate the in vivo net flux of PGE 2 transport at the BBB and compare the elimination capacities between the BBB and BCSFB in order to understand the role of the BBB in the modulation of PGE 2 concentration in the brain.
The level of L-glutamate (L-Glu), one of the excitatory neurotransmitters, is also increased in patients with CNS diseases involving neuroexcitation and neurotoxicity, such as convulsions and Alzheimer's disease. 21, 22) The concentration of L-Glu in the brain ISF and CSF is maintained at a few µM under normal conditions. 23, 24) In various neuroexcitatory diseases, it has been reported that the concentration of L-Glu in the brain is raised to ³10 mM as the average concentration in neuroexcitatory diseases because L-Glu (³100 mM) in synaptic vesicles of the presynaptic terminal is actively released into the synaptic cleft. [25] [26] [27] The local excess release of L-Glu leads to an increase in the intracellular concentration of calcium ions ([Ca 2+ ] i ) via the activation of L-Glu receptors, such as N-methyl-D-aspartate (NMDA)-type L-Glu receptors (NMDA-R) and metabotropic L-Glu receptors (mGluR). 21) It has been reported that the activation of NMDA-R increases the extracellular concentration of PGE 2 because of the up-regulation of PGE 2 -synthesizing enzymes. 28) Hence, there is a possibility that the concentration of PGE 2 in the brain is affected by the intracerebral accumulation of L-Glu and thus the activation of L-Glu receptors. However, changes in the inactivation of PGE 2 in the brain, namely the elimination of PGE 2 in the brain across the BBB, by an intracerebral excess of L-Glu has not yet been elucidated.
The purpose of this study was to investigate the brain-to-blood efflux transport of PGE 2 across the BBB by combining brain efflux index (BEI) and brain slice uptake studies in rats. Moreover, the alteration of PGE 2 efflux transport at the BBB and associated factors by intracerebral excess of L-Glu was evaluated by a BEI study after pre-administration of L-Glu and compounds which are agonists and antagonists for L-Glu receptors.
Materials and Methods
Animals: Adult male Wistar rats (150-250 g) were purchased from Japan SLC (Hamamatsu, Japan). They were maintained in a controlled environment and all experiments were approved by the Animal Care Committee, University of Toyama.
Reagents: [5, 6, 8, 11, 12, 14, Brain efflux index study: In vivo rat BBB-mediated efflux transport was evaluated using an intracerebral microinjection technique: the BEI method.
34) The detailed procedure is described in the Supplemental materials.
In pre-administration studies, a compound solution ( 17,35) As a control, ECF buffer, with or without 0.2% DMSO, was injected. The concentration of intracerebrally-injected agonists and antagonists was more than 10-fold higher than the reported EC 50 and IC 50 values of these compounds for targeted L-Glu receptors. 36, 37) The BEI value was defined according Eq. (1) 
where V d,brain represents the distribution volume determined by an in vitro brain slice uptake study as described below.
In vitro rat brain slice uptake: The [ 3 H]PGE 2 uptake study using brain slices was performed as described previously with minor modifications.
34) The detailed procedure is included in the Supplemental materials. Because no significant difference in the slice/medium ratio of [ 
Immunoblot analysis: Under pentobarbital anesthesia (50 mg/kg body weight, i.p.), the rat brain was excised 15 min after pre-administration to the cerebral cortex of ECF buffer or 50 mM L-Glu. A crude membrane protein of the ipsilateral cerebrum was prepared as described previously. 14) The details are included in the Supplemental materials. Crude membrane protein (50 µg) was separated on a sodium dodecyl sulfate-polyacrylamide gel and subsequently electrotransferred to a polyvinylidene difluoride membrane. Following incubation with Tris-buffered saline (25 mM Tris-HCl and 125 mM NaCl, pH 7.4) containing 0.1% Tween-20 and 5% skimmed milk for 12 h at 4°C, the membranes were incubated with guinea pig polyclonal anti-microsomal PGES-1 antibody (0.5 µg/mL) for 12 h at 4°C. 14) Subsequently, the membranes were incubated with horseradish peroxidase-conjugated anti-guinea pig antibody. The bands were then visualized with an enhanced chemiluminescence kit (ECL Prime Western Blotting Detection System; GE healthcare, Chalfont St. Giles, UK).
Data analysis: The kinetic parameters determined by the least-squares regression analysis (k eff and CL BBB,eff ) are presented as the mean « SD. Other data represent the mean « SEM. The statistical significance of differences between the means was determined by using the unpaired two-tailed Student's t-test for two groups and one-way analysis of variance followed by Dunnett's test or the Tukey-Kramer method for more than two groups.
Results

Apparent elimination clearance of [
3 H]PGE 2 across the BBB in rats: Figure 1A shows Figure 1B , the apparent slice/medium ratio exhibited a timedependent increase for up to 20 min. Because no significant difference in the slice/medium ratio between 20 min and 60 min incubation was observed (p = 0.113), the steady-state slice/medium ratio was defined as that at 60 min, so that the V ]PGE 2 at 20 min after microinjection was determined following pre-administration of L-Glu. As shown in Figure 3A , the pre-administration of 50 mM L-Glu decreased the BEI value of [ 3 H]PGE 2 by 28%. In contrast, the [ 3 H]PGE 2 BEI value was not significantly affected by the pre-administration of L-Glu at concentrations of 0.1, 1, or 10 mM. In immunoblot studies using antibodies for microsomal PGES-1, 14) which is an inducible enzyme for PGE 2 synthesis, the cerebral protein expression of microsomal PGES-1 at 25 min after the pre-administration of 50 mM L-Glu was not altered compared with that after preadministration of ECF buffer ( Supplementary Fig. S1 ).
It has been reported that L-Glu increases [Ca 2+ ] i via L-Glu receptors at the plasma membrane of neural cells. 21) We examined the effect of a calcium chelator, BAPTA-AM, 39) on L-Glu-induced attenuation of BBB-mediated PGE 2 elimination. The BEI value of [ 3 H]PGE 2 after the pre-administration of both 50 mM L-Glu and 100 µM BAPTA-AM was found to be 52.6 « 6.1%. This value was significantly greater (1.5-fold) than that after pre-administration of 50 mM L-Glu alone (35.2 « 4.1%) and this was not significantly different from the control (50.5 « 2.4%) (Fig. 3B) .
Effect of L-Glu receptor agonists on [ ] i has been reported to have occurred via NMDA-R or mGluR. To elucidate the involvement of these L-Glu receptors on PGE 2 elimination across the BBB, the effect of the activation of NMDA-R or mGluR on BBB-mediated [ 3 H]PGE 2 elimination was assessed. The activation of NMDA-R was induced by the preadministration of both 10 mM NMDA and 10 mM D-Ser, which are co-agonists of NMDA-R, 40) while mGluR was activated by the pre-administration of 10 mM t-ACPD, an agonist of mGluR. 41) As shown in Figure 4 , the pre-administration of both NMDA and D-Ser decreased the BEI value of [ (Fig. 5) . As NMDA-R antagonists, we used a non-competitive antagonist, MK-801, and a competitive antagonist, D-AP5. 42, 43) In the presence of 1 mM MK-801, L-Glu pre-administration did not significantly reduce the BEI value (46.0 « 1.6%) of [ 3 H]PGE 2 compared with the control (Fig. 5A) . Similarly, the BEI value was not significantly altered by L-Glu preadministration in the presence of 1 mM D-AP5 (48.3 « 11.7%; Fig. 5B ).
Discussion
In the present study, we investigated PGE 2 elimination from the brain across the BBB in rats (Fig. 1) , and its inhibition by intracerebral administration of substrates of Oat3 and Mrp4 (Fig. 2) . This elimination across the BBB is also attenuated by intracerebral administration of excess L-Glu (Fig. 3) . By using agonists or antagonists of L-Glu receptors, we found that NMDA-type L-Glu receptors (NMDA-R) are involved in L-Glu-mediated attenuation of PGE 2 elimination across the BBB (Figs. 4 and 5) .
Intracerebral [ 3 H]PGE 2 , which was injected into the cerebral cortex, was eliminated across the BBB with a half-life of 14 min 2 , benzylpenicillin, and Ro64-0802 after the co-administration of each compound were estimated as ³65 µM, ³2.2 mM, and ³4.3 mM, respectively, from the injectate concentration divided by the dilution factor (i.e. 46.2 at 20 min), which was reported previously. 34) These expected cerebral concentrations of compounds are indicated by the number given in parentheses. Each column represents the mean « SEM (n = 4-7). **p < 0.01, significantly different from the control. in rats (Fig. 1A) . This value is consistent with that in mice (16 min), 17) suggesting that PGE 2 in the brain was eliminated across the BBB in rats in the same manner as in mice. Moreover, the CL BBB,eff of PGE 2 from the cerebral cortex across the BBB in rats was initially determined as 60.1 µL/(min0g brain) (Fig. 1) . Eguchi et al. reported that intravenously administered [ 3 H]PGE 2 was transported to the cerebral cortex in rats with an estimated bloodto-brain influx clearance (CL BBB,inf ) of 30.0 µL/(min0g brain), 19) which is 2-fold lower than the CL BBB,eff of [ 3 H]PGE 2 . Therefore, the net flux of PGE 2 transport across the BBB is suggested to be dominated by brain-to-blood efflux transport. In rats, the PGE 2 concentrations in the brain ISF and plasma have been reported to be 0.9-1.5 nM and 17 nM, respectively. 3, 44) It is considered that the 2-fold higher CL BBB,eff relative to CL BBB,inf is at least partly involved in the difference of PGE 2 concentration between the brain ISF and plasma. Our previous study revealed that the BCSFB takes part in PGE 2 elimination from the CSF with an apparent elimination clearance of PGE 2 from the CSF (CL CSF ) of 39.5 µL/(min0rat). 14) Because it is assumed that the brain weight equals 1.6 g per rat, 45) the CL BBB,eff was found to be 96.2 µL/(min0rat), which is 2.4-fold greater than this CL CSF value. In addition, it is reported that PGE 2 -inactivating enzyme is hardly functionalized in the brain parenchyma. 6) Taking these lines of evidence into consideration, it is suggested that PGE 2 elimination across the BBB is one of the important pathways for PGE 2 clearance from the brain.
[ 3 H]PGE 2 elimination across the BBB in rats was inhibited by unlabeled PGE 2 (Fig. 2) , indicating carrier-mediated PGE 2 efflux across the BBB. In mice, PGE 2 elimination across the BBB was inhibited by intracerebral/intravenous administration of cephalosporins, which are substrates/inhibitors of Mrp4. 17, 46) In rats, [ 3 H]PGE 2 elimination across the BBB was strongly inhibited by the co-administration of benzylpenicillin, a typical substrate of rat Oat3, and Mrp4, 9, 31) at an intracerebral concentration of ³22 mM. Moreover, Ro64-0802, which is reported to be a substrate of Oat3 and Mrp4, 38) at an intracerebral concentration of 4.3 mM inhibited [ 3 H]PGE 2 elimination across the rat BBB by approximately 60% (Fig. 2) . Taking these points into consideration, it appears that Oat3 and/or Mrp4 is mainly involved in PGE 2 elimination from rat brain across the BBB.
The accumulation of PGE 2 in the brain induces the cerebral inflammatory responses in neural excitatory diseases such as a seizure and Alzheimer's disease. PGE 2 elimination across the BBB is also inhibited by the pre-administration of L-Glu at a concentration of 50 mM, and is not significantly altered by a concentration of 0.1, 1, 10 mM (Fig. 3A) . Although mPGES-1 is reported to be involved in the overproduction of PGE 2 by L-Glu treatment for 24 h of mouse hippocampal slices, 47) the expression of mPGES-1 in the rat ipsilateral cerebrum after pre-administration of 50 mM LGlu in the brain was not altered (Supplementary Fig. S1 ). Thus, it appears that the intracerebral pre-administration of 50 mM LGlu attenuates PGE 2 elimination across the BBB and does not upregulate mPGES-1 expression in the brain. The concentration of LGlu in synaptic vesicles of the presynaptic terminal is reported to reach ³100 mM. L-Glu in the synaptic vesicles is actively released by the excitatory neuronal signals in neuroexcitatory and neuroinflammatory diseases, such as a seizure, cerebral ischemia and Alzheimer's disease, and the concentration of L-Glu in the synaptic cleft is locally elevated. [25] [26] [27] Because it has been unclear whether the local concentration of L-Glu under these diseases reaches ³50 mM, further studies are needed to evaluate the PGE 2 elimination across the BBB in animal models of these diseases. Nevertheless, it is possible that the attenuation of PGE 2 elimination across the BBB, but not the up-regulation of mPGES-1 protein expression in the brain, is involved in an early stage of the increase in cerebral PGE 2 level and the pathogenesis of inflammatory responses in neuroexcitatory and neuroinflammatory diseases with the release of L-Glu in synaptic vesicles.
It is believed that the inhibition of PGE 2 elimination across the BBB by intracerebral L-Glu is caused in an indirect manner. Our previous studies have revealed that the carrier-mediated efflux transport of L-aspartate was inhibited by L-Glu at intracerebral concentrations of 3.3 mM and 100 mM, 48) whereas there is no report that PGE 2 is a substrate of L-aspartate transporters, such as alanine-serine-cysteine transporters and excitatory amino acid transporters. It has also been reported that Oat3 is down-regulated by the activation of protein kinase C, 49) which is activated by an increase in [Ca 2+ ] i . 50) The BBB expresses several L-Glu receptors, such as NMDA-R and mGluR, [51] [52] [53] the activation of which increases [Ca 2+ ] i . 21, 54) Intracerebral administration of L-Glu in the presence of BAPTA-AM, which is a plasma membrane-permeant chelator and inhibits Ca 2+ -dependent intracellular functions at the concentration below 100 µM, 55, 56) abolished [ 3 H]PGE 2 elimination across the rat BBB (Fig. 3B) . Therefore, it is suggested that intracerebral L-Glu administration results in PGE 2 elimination across the BBB via an increased [Ca 2+ ] i . The increase in [Ca 2+ ] i by L-Glu in neural cells is known to be induced via the activation of NMDA-R and mGluR. [ 3 H]PGE 2 elimination across the BBB was inhibited by the administration of NMDA and D-Ser, whereas it was not affected by the pre-administration of t-ACPD (Fig. 4) . Moreover, the inhibitory effect of the pre-administration of L-Glu on [ (Fig. 5) . It has been reported that NMDA-R subunit NR1 is expressed in rat and human brain capillaries. 51, 57) Although the relationship between the activation of NMDA-R and the down-regulation of transporters which are responsible for PGE 2 elimination, such as Oat3, has been unclear, it is considered that the activation of NMDA-R, but not mGluR, in neural cells including brain capillary endothelial cells is involved in the attenuation of PGE 2 elimination across the BBB induced by intracerebral excess L-Glu. It has been reported that the activation of NMDA-R plays a role in the progression of Alzheimer's disease. 21) The PGE 2 concentration in the CNS is reported to be increased in patients suffering from neurodegenerative diseases, such as Alzheimer's disease. 58) Thus, it is likely that the attenuation of PGE 2 elimination across the BBB by the activation of NMDA-R in Alzheimer's disease plays a role in the increase in the PGE 2 concentration in the brain.
Memantine, an antagonist of NMDA-R, has advantages in the treatment of Alzheimer's disease compared with inhibitors of choline esterase, such as donepezil. 22) In Alzheimer's disease, neuroinflammation and neurodegeration are observed, and memantine attenuates these responses. It has been reported that PGE 2 induces neuroinflammation and neurotoxicity. 1, 2) Because the antagonism of NMDA-R under the condition of excess L-Glu in the brain abolishes the attenuation of PGE 2 elimination across the BBB (Fig. 5) , it is considered that NMDA-R antagonists, including memantine, reduce the PGE 2 concentration in the brain under neuroexcitatory conditions, such as Alzheimer's disease, and attenuate PGE 2 -induced neuroinflammatory responses. Consequently, it is possible that the normalization of PGE 2 elimination across the BBB by antagonists of NMDA-R under the condition of intracerebral excess L-Glu accounts, at least in part, for the benefits of prescription of memantine in Alzheimer's disease.
In conclusion, PGE 2 is predominantly eliminated from the rat brain across the BBB via Oat3 and/or Mrp4. The elimination of PGE 2 from the brain across the BBB is attenuated by intracerebral excess L-Glu via the activation of NMDA-R. These findings provide a new insight into the role of BBB-mediated PGE 2 efflux in the modulation of the intracerebral PGE 2 concentration and its alteration in neuroexcitatory diseases.
